Protein / target

Interleukin-17 receptor A

Encoded byIL17RAQ96F46Homo sapiensSwiss-Prot

UniProt: Q96F46 Ensembl: ENSG00000177663 HGNC: HGNC:5985 NCBI Gene: 23765

Clinically validated

Therapeutic maturity

Approved medicines

Open Targets target-level

View by indication →

Clinical trials

Antibody-tractable

Druggability

Approved Drug

Protein at a glance

Biological role

Interleukin-17 receptor

Strongest disease association

Psoriasis

Via encoding gene IL17RA · Genetic evidence · score 0.40

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.

View complete UniProt function annotation

Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A (PubMed:17911633, PubMed:9367539). Receptor for IL17F (PubMed:17911633, PubMed:19838198). Binds to IL17A with higher affinity than to IL17F (PubMed:17911633). Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC (PubMed:16785495). Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC (PubMed:18684971). Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:16785495, PubMed:17911633, PubMed:18684971, PubMed:21350122, PubMed:24120361). Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Plays a role in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. Contributes to Influenza virus clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity). Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848)

Subcellular location

Cell membraneSecreted

Domains and Gene Ontology detail (26)

Domains & features

SEFIR

Gene Ontology

Cextracellular region
Cplasma membrane
Finterleukin-17 receptor activity
Fsignaling receptor binding
Pcell surface receptor signaling pathway
Pdefense response to fungus
Pfibroblast activation
Pgranulocyte chemotaxis
Pinflammatory response
Pinnate immune response
Pinterleukin-17-mediated signaling pathway
Pinterleukin-17A-mediated signaling pathway

866 aa · 96 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOImmune signallingUniProt · GO

View supporting evidence

Cell migration

·granulocyte chemotaxis

Immune signalling

·Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune sys…
·interleukin-17 receptor activity
·inflammatory response
·innate immune response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Immune System Diseases1 medicine

brodalumab

Psoriasis1 medicine

brodalumab

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

brodalumab

Narrow target profileApprovedAntagonist

Interleukin-17 receptor A antagonist

Indicated for Immune System Diseases, Psoriasis

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL17RA

Gene-level evidence surfaced through the gene IL17RAthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Psoriasis

0.84Well supported

Clinical evidence dominant · Open Targets 0.66

Psoriasis vulgaris

0.72Moderately supported

Clinical evidence dominant · Open Targets 0.58

Arthritis, Psoriatic

0.65Moderately supported

Clinical evidence dominant · Open Targets 0.53

Pustular psoriasis

0.63Moderately supported

Clinical evidence dominant · Open Targets 0.51

Immune System Diseases

0.46Limited support

Clinical evidence dominant · Open Targets 0.37

View evidence synthesis (5)

PsoriasisWell supported

0.84

agreement 0.73–0.94

Clinical61%Genetic34%Literature5%

Open Targets aggregate 0.66 · 3 independent evidence families

Psoriasis vulgarisModerately supported

0.72

agreement 0.56–0.87

Clinical98%Literature2%

Open Targets aggregate 0.58 · 2 independent evidence families

Arthritis, PsoriaticModerately supported

0.65

agreement 0.50–0.81

Clinical96%Literature4%

Open Targets aggregate 0.53 · 2 independent evidence families

Pustular psoriasisModerately supported

0.63

agreement 0.48–0.79

Clinical98%Literature2%

Open Targets aggregate 0.51 · 2 independent evidence families

Immune System DiseasesLimited support

0.46

agreement 0.30–0.61

Clinical99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Psoriasis0.66

Psoriasis vulgaris0.58

Arthritis, Psoriatic0.53

Pustular psoriasis0.51

COVID-190.39

Immune System Diseases0.37

Scleroderma, Systemic0.29

Drug development

1 compounds recorded · 1 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (1)

BRODALUMABApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Strong

Approved Drug and UniProt loc high conf support this modality.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)

AB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque PsoriasisPHASE4

ACTIVE_NOT_RECRUITING · via brodalumab · NCT03240809

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot StudyPHASE1

RECRUITING · via brodalumab · NCT06673329

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body WeightPHASE4

COMPLETED · via brodalumab · NCT04306315

Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to UstekinumabPHASE4

TERMINATED · via brodalumab · NCT04533737

View all trials (25)

Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar PsoriasisPHASE4

UNKNOWN · via brodalumab · NCT04622033

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio StudyPHASE4

COMPLETED · via brodalumab · NCT04340076

Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe PsoriasisPHASE4

UNKNOWN · via brodalumab · NCT03478280

A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque PsoriasisPHASE4

COMPLETED · via brodalumab · NCT03331835

A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A TherapiesPHASE4

COMPLETED · via brodalumab · NCT03403036

A Phase 3, Randomised, Double-blind, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Brodalumab Treatment Compared to Placebo and Ustekinumab in Adolescent Subjects With Moderate-to-severe Plaque PsoriasisPHASE3

TERMINATED · via brodalumab · NCT04305327

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Axial SpondyloarthritisPHASE3

COMPLETED · via brodalumab · NCT02985983

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2PHASE3

COMPLETED · via brodalumab · NCT02024646

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1PHASE3

TERMINATED · via brodalumab · NCT02029495

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3PHASE3

TERMINATED · via brodalumab · NCT01708629

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1PHASE3

TERMINATED · via brodalumab · NCT01708590

TERMINATED · via brodalumab · NCT01708603

Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque PsoriasisPHASE3

TERMINATED · via brodalumab · NCT02786732

An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis SuppurativaPHASE2

UNKNOWN · via brodalumab · NCT03910803

A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial SpondyloarthritisPHASE2

WITHDRAWN · via brodalumab · NCT02429882

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator ReversibilityPHASE2

TERMINATED · via brodalumab · NCT01902290

A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's DiseasePHASE2

TERMINATED · via brodalumab · NCT01199302

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's DiseasePHASE2

TERMINATED · via brodalumab · NCT01150890

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to MethotrexatePHASE2

COMPLETED · via brodalumab · NCT00950989

A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid ArthritisPHASE1/PHASE2

COMPLETED · via brodalumab · NCT00771030

A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa PatientsEARLY_PHASE1

COMPLETED · via brodalumab · NCT04979520

An Alternative Dose Interval Study to Examine Safety and Identify Potential Biomarkers in Participants With Hidradenitis Suppurativa Receiving BrodalumabEARLY_PHASE1

WITHDRAWN · via brodalumab · NCT04249713

A Pilot Study of Safety and Biomarkers In Hidradenitis Suppurativa Participants Receiving BrodalumabEARLY_PHASE1

COMPLETED · via brodalumab · NCT03960268

A Bioequivalence Study Comparing a Single Subcutaneous Injection With a 1.5 mL Prefilled Syringe Versus 2 Subcutaneous Injections of 1 mL and 0.5 mL Prefilled Syringes of Brodalumab 140 mg/mL to Healthy SubjectsPHASE1

COMPLETED · via brodalumab · NCT02173392

An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque PsoriasisPHASE1

COMPLETED · via brodalumab · NCT01937260

ClinicalTrials.gov via the drug-target graph.

What's happening now

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

Regulatory approval2017-07-17
Approval: Kyntheum (EMA)
ema · regulatory · ema · via brodalumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.